BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 14519637)

  • 21. Overexpression and mutation of p53 in epithelial ovarian cancer.
    Marks JR; Davidoff AM; Kerns BJ; Humphrey PA; Pence JC; Dodge RK; Clarke-Pearson DL; Iglehart JD; Bast RC; Berchuck A
    Cancer Res; 1991 Jun; 51(11):2979-84. PubMed ID: 2032235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line.
    Cinti C; Claudio PP; Luca AD; Cuccurese M; Howard CM; D'Esposito M; Paggi MG; Sala DL; Azzoni L; Halazonetis TD; Giordano A; Maraldi NM
    Oncogene; 2000 Oct; 19(44):5098-105. PubMed ID: 11042698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma.
    Leitao MM; Soslow RA; Baergen RN; Olvera N; Arroyo C; Boyd J
    Gynecol Oncol; 2004 May; 93(2):301-6. PubMed ID: 15099937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer.
    Kohler MF; Kerns BJ; Humphrey PA; Marks JR; Bast RC; Berchuck A
    Obstet Gynecol; 1993 May; 81(5 ( Pt 1)):643-50. PubMed ID: 8469448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.
    Buller RE; Lallas TA; Shahin MS; Sood AK; Hatterman-Zogg M; Anderson B; Sorosky JI; Kirby PA
    Clin Cancer Res; 2001 Apr; 7(4):831-8. PubMed ID: 11309330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer.
    Dong M; Nio Y; Yamasawa K; Toga T; Yue L; Harada T
    J Surg Oncol; 2003 Feb; 82(2):111-20. PubMed ID: 12561067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
    Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
    Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer.
    Goodheart MJ; Ritchie JM; Rose SL; Fruehauf JP; De Young BR; Buller RE
    Clin Cancer Res; 2005 May; 11(10):3733-42. PubMed ID: 15897570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural assessment of single amino acid mutations: application to TP53 function.
    Yip YL; Zoete V; Scheib H; Michielin O
    Hum Mutat; 2006 Sep; 27(9):926-37. PubMed ID: 16917930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An abundance of p53 null mutations in ovarian carcinoma.
    Skilling JS; Sood A; Niemann T; Lager DJ; Buller RE
    Oncogene; 1996 Jul; 13(1):117-23. PubMed ID: 8700537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
    Chang SC; Lin JK; Lin TC; Liang WY
    Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. P53 mutations in colorectal cancer assessed in both genomic DNA and cDNA as compared to the presence of p53 LOH.
    Forslund A; Kressner U; Lönnroth C; Andersson M; Lindmark G; Lundholm K
    Int J Oncol; 2002 Aug; 21(2):409-15. PubMed ID: 12118339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. P53 mutation does not affect prognosis in ovarian epithelial malignancies.
    Fallows S; Price J; Atkinson RJ; Johnston PG; Hickey I; Russell SE
    J Pathol; 2001 May; 194(1):68-75. PubMed ID: 11329143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
    Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
    Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p53 mutations in L3-loop zinc-binding domain, DNA-ploidy, and S phase fraction are independent prognostic indicators in colorectal cancer: a prospective study with a five-year follow-up.
    Russo A; Migliavacca M; Zanna I; Valerio MR; Latteri MA; Grassi N; Pantuso G; Salerno S; Dardanoni G; Albanese I; La Farina M; Tomasino RM; Gebbia N; Bazan V
    Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1322-31. PubMed ID: 12433709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p53 gene mutations in breast cancers in midwestern US women: null as well as missense-type mutations are associated with poor prognosis.
    Saitoh S; Cunningham J; De Vries EM; McGovern RM; Schroeder JJ; Hartmann A; Blaszyk H; Wold LE; Schaid D; Sommer SS
    Oncogene; 1994 Oct; 9(10):2869-75. PubMed ID: 8084591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.
    Kato S; Han SY; Liu W; Otsuka K; Shibata H; Kanamaru R; Ishioka C
    Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8424-9. PubMed ID: 12826609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers.
    Aghmesheh M; Nesland JM; Kaern J; Dorum A; Edwards L; Byth K; Friedlander M; Jackson P; Tucker KM; Russell PJ
    Gynecol Oncol; 2004 Dec; 95(3):430-6. PubMed ID: 15581943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
    Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
    Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
    J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.